Skip to content

Biosimilars, Biologics, FDA Policy and Approvals, Clinical Trials, and Specialty Pharmacy

  • Home
    • Home
  • About BR&R
  • Biosimilar Approval Status
  • BR&R Product Profiles
    • Abrilada
    • Amjevita
    • Avasola
    • Byooviz
    • Cyltezo
    • Erelzi
    • Eticovo
    • Fulphila
    • Fylnetra
    • Hadlima
    • Herzuma
    • Hulio
    • Hyrimoz
    • Inflectra
    • Kanjinti
    • Mvasi
    • Nivestym
    • Nyvepria
    • Ogivri
    • Ontruzant
    • Releuko
    • Renflexis
    • Retacrit
    • Rezvoglar
    • Riabni
    • Ruxience
    • Semglee
    • Trazimera
    • Truxima
    • Udenyca
    • Yusimry
    • Zarxio
    • Ziextenzo
    • Zirabev
  • Contact Us
  • The 2023 Biosimilars Market Report
  • $0.00 0 items

Cart

Your cart is currently empty.

Return to shop

SM Health Comm

Recent Posts

  • J&J Slaps Patent Suit on Amgen Over Impending Stelara® Biosimilar December 2, 2022
  • A Conversation With Ian Henshaw November 29, 2022
  • Lilly’s Rezvoglar Joins the Ranks of the Interchangeable Insulins November 18, 2022
  • OptumRx Reveals a 2023 Decision on Adalimumab Biosimilars November 16, 2022
  • What We May Have Here Is a Failure to Communicate November 9, 2022
  • Can Biosimilars Fund New Specialty Pipeline Development? October 18, 2022
  • Biosimilar Bytes October 6, 2022
  • Celltrion Earns FDA Nod for Bevacizumab Biosimilar September 29, 2022
  • FDA’s BsUFA III Features September 28, 2022
  • The Inflation Reduction Act: Reducing Drug Prices and Maybe Future Biosimilar Development September 22, 2022

Recent Comments

J&J Slaps Patent… on Ustekinumab Biosimilars Update
J&J Slaps Patent… on Preliminary Phase 3 Study Data…
Lilly's Rezvogl… on Insulin Wars: Biosimilar Susta…
Cooking Katie on Pfizer Launches Ruxience, Anno…
FDA's BsUFA III… on Sandoz Submits 351(k) Applicat…

Archives

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Top Posts & Pages

  • J&J Slaps Patent Suit on Amgen Over Impending Stelara® Biosimilar
  • Biosimilar Approval Status
  • The Evolution of the Biosimilars Market
  • A Conversation With Ian Henshaw
  • The Next-Generation Biosimilar Race: A Tale of Two Autoimmune Biologics
  • Semglee
  • Tocilizumab Biosimilars Approaching: Developments on Three Fronts
  • Ustekinumab Biosimilars Update
  • Amjevita
  • Who Are the Key Aflibercept Biosimilar Players to Watch?
Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookie Policy

Follow Us

  • Twitter
  • LinkedIn
  • Home
  • About BR&R
  • Biosimilar Approval Status
  • Contact Us
  • Terms and Conditions

Copyright

Copyright 2013-2022 by SM Health Communications. All Rights Reserved

Powered by WordPress.com.